ERBB2 and breast cancer: Based on the aforementioned findings, we hypothesized that in patients with HER2+ breast cancer treated with the combination of lapatinib and trastuzumab plus cytotoxic chemotherapy, a decrease in the CSC population correlates with response to therapy.